NASDAQ:RXRX Recursion Pharmaceuticals (RXRX) Stock Price, News & Analysis $5.36 -0.17 (-2.98%) As of 11:04 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Recursion Pharmaceuticals Stock (NASDAQ:RXRX) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get RXRX alerts:Sign Up Key Stats Today's Range$5.35▼$5.6050-Day Range$4.52▼$5.9552-Week Range$3.79▼$12.36Volume11.26 million shsAverage Volume25.11 million shsMarket Capitalization$2.33 billionP/E RatioN/ADividend YieldN/APrice Target$7.25Consensus RatingHold Company Overview Recursion Pharmaceuticals, Inc. (NASDAQ: RXRX) is a biopharmaceutical company that combines advanced automation, artificial intelligence and high-throughput biology to discover and develop novel therapeutics. The company’s proprietary platform integrates deep-learning algorithms with large-scale cellular imaging and chemical biology, enabling the rapid identification of potential drug candidates across a range of indications. By automating complex laboratory workflows and leveraging computational models, Recursion aims to accelerate the drug discovery process and expand the scope of targets that can be addressed. At the core of Recursion’s offering is its digital biology platform, which captures billions of cell images under varying chemical and genetic perturbations. These data feed into proprietary machine-learning pipelines designed to uncover subtle phenotypic changes that traditional screening methods might miss. The company applies this approach to diverse therapeutic areas, including rare genetic diseases, oncology and immunology, with several preclinical programs in its pipeline. Partnerships with pharmaceutical firms and research institutions further extend Recursion’s reach and validate its platform in real-world drug discovery projects. Founded in 2013 by Christopher Gibson and Blake Borgeson, Recursion Pharmaceuticals is headquartered in Salt Lake City, Utah, and maintains additional research facilities and corporate offices across North America and Europe. Following its initial public offering in early 2021, the company has continued to expand both its technological capabilities and its therapeutic focus. Led by CEO Christopher Gibson and a management team versed in biology, data science and automation engineering, Recursion is positioned to advance a new paradigm in drug discovery that bridges experimental data with predictive, AI-driven insights.AI Generated. May Contain Errors. Read More Recursion Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks50th Percentile Overall ScoreRXRX MarketRank™: Recursion Pharmaceuticals scored higher than 50% of companies evaluated by MarketBeat, and ranked 574th out of 938 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingHold Consensus RatingRecursion Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.17, and is based on 2 buy ratings, 3 hold ratings, and 1 sell rating.Upside PotentialRecursion Pharmaceuticals has a consensus price target of $7.25, representing about 34.1% upside from its current price of $5.41.Amount of Analyst CoverageRecursion Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Recursion Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Recursion Pharmaceuticals are expected to grow in the coming year, from ($1.57) to ($1.42) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Recursion Pharmaceuticals is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Recursion Pharmaceuticals is -3.04, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRecursion Pharmaceuticals has a P/B Ratio of 2.07. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Recursion Pharmaceuticals' valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted39.65% of the float of Recursion Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRecursion Pharmaceuticals has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Recursion Pharmaceuticals has recently increased by 6.42%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldRecursion Pharmaceuticals does not currently pay a dividend.Dividend GrowthRecursion Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted39.65% of the float of Recursion Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverRecursion Pharmaceuticals has a short interest ratio ("days to cover") of 5.3.Change versus previous monthShort interest in Recursion Pharmaceuticals has recently increased by 6.42%, indicating that investor sentiment is decreasing significantly. News and Social Media3.2 / 5News Sentiment0.75 News SentimentRecursion Pharmaceuticals has a news sentiment score of 0.75. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Recursion Pharmaceuticals this week, compared to 10 articles on an average week.Search Interest111 people have searched for RXRX on MarketBeat in the last 30 days. This is an increase of 79% compared to the previous 30 days.MarketBeat Follows48 people have added Recursion Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 118% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Recursion Pharmaceuticals insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $202,026.00 in company stock.Percentage Held by InsidersOnly 8.43% of the stock of Recursion Pharmaceuticals is held by insiders.Percentage Held by Institutions89.06% of the stock of Recursion Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Recursion Pharmaceuticals' insider trading history. Receive RXRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Recursion Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. RXRX Stock News HeadlinesNeedham Reiterates a Buy on Recursion Pharmaceuticals (RXRX)September 30, 2025 | insidermonkey.comJim Cramer on Recursion: “I Need to See a Proof of Concept Here”September 29, 2025 | insidermonkey.com9 AI Stocks Set to Soar Amid U.S.-China Trade TensionsThe escalating U.S.-China trade tensions are reshaping the AI landscape. Companies like Nvidia are facing significant revenue hits with the U.S. imposing new export restrictions on advanced AI chips to China. This shift opens doors for U.S.-based AI companies poised to fill the gap.October 7 at 2:00 AM | StockEarnings (Ad)The Biotech Stock That's Too Risky for Most InvestorsSeptember 28, 2025 | fool.comDoes Short Squeeze Attention and AI Advances Alter the Bull Case for Recursion Pharmaceuticals (RXRX)?September 27, 2025 | finance.yahoo.com10 Hidden-Gem AI Stocks to Buy Right NowSeptember 27, 2025 | fool.comPrediction: 2 Stocks That Will Be Worth More Than BigBear.ai 5 Years From NowSeptember 26, 2025 | fool.comLooking for the Next Big Pop? Here’s Why Recursion Pharmaceuticals (RXRX) Could Do a Dead-Cat BounceSeptember 25, 2025 | msn.comSee More Headlines RXRX Stock Analysis - Frequently Asked Questions How have RXRX shares performed this year? Recursion Pharmaceuticals' stock was trading at $6.76 at the start of the year. Since then, RXRX shares have decreased by 20.0% and is now trading at $5.4050. How were Recursion Pharmaceuticals' earnings last quarter? Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) announced its quarterly earnings results on Tuesday, August, 5th. The company reported ($0.41) earnings per share for the quarter, missing analysts' consensus estimates of ($0.35) by $0.06. The company's quarterly revenue was up 33.3% on a year-over-year basis. Read the conference call transcript. When did Recursion Pharmaceuticals IPO? Recursion Pharmaceuticals (RXRX) raised $306 million in an IPO on Friday, April 16th 2021. The company issued 18,000,000 shares at $16.00-$18.00 per share. Goldman Sachs, J.P. Morgan, BofA Securities, SVB Leerink, Allen & Co. and KeyBanc Capital Markets served as the underwriters for the IPO. How do I buy shares of Recursion Pharmaceuticals? Shares of RXRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Recursion Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Recursion Pharmaceuticals investors own include NVIDIA (NVDA), Invesco QQQ (QQQ), Meta Platforms (META), Broadcom (AVGO), CrowdStrike (CRWD) and Advanced Micro Devices (AMD). Company Calendar Last Earnings8/05/2025Today10/07/2025Next Earnings (Estimated)11/05/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:RXRX CIK1601830 Webwww.recursion.com Phone385-269-0203Fax801-821-2872Employees400Year Founded2013Price Target and Rating Average Price Target for Recursion Pharmaceuticals$7.25 High Price Target$10.00 Low Price Target$5.00 Potential Upside/Downside+31.1%Consensus RatingHold Rating Score (0-4)2.17 Research Coverage6 Analysts Profitability EPS (Trailing Twelve Months)($1.78) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$463.66 million Net Margins-1,004.91% Pretax Margin-1,004.88% Return on Equity-76.09% Return on Assets-54.29% Debt Debt-to-Equity Ratio0.02 Current Ratio3.58 Quick Ratio3.58 Sales & Book Value Annual Sales$58.84 million Price / Sales40.80 Cash FlowN/A Price / Cash FlowN/A Book Value$2.61 per share Price / Book2.12Miscellaneous Outstanding Shares434,150,000Free Float397,553,000Market Cap$2.40 billion OptionableOptionable Beta0.91 Social Links 7 Stocks That Could Be Bigger Than Tesla, Nvidia, and GoogleLooking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.Get This Free Report This page (NASDAQ:RXRX) was last updated on 10/7/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredAn $8 trillion-dollar discovery 17,000 ft underwater A strange rock pulled from the ocean floor may hold the key to a $16 trillion resource boom. Inside it: materi...Porter & Company | SponsoredThe Tiny Stock Set to Soar with Musk's AI AmbitionsThe Tiny Stock Set to Soar with Musk's AI Ambitions While Musk builds one of the most ambitious AI empires ...Behind the Markets | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | Sponsored$100 Trillion “AI Metal” Found in American Ghost TownJeff Brown recently traveled to a ghost town in the middle of an American desert… To investigate what could...Brownstone Research | SponsoredStunning new initiative unfolding in the White House?what I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredForget AI Stocks — This Device Will REPLACE the MicrochipWhile everyone's chasing the same AI plays, George Gilder is focused on something completely different. He ...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Recursion Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Recursion Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.